Cargando…
Pediatric precision oncology: “better three hours too soon than a minute too late”
Precision oncology is defined as the selection of an effective treatment for a cancer patient based upon genomic profiling of the patient’s tumor to identify targetable alterations. The application of precision oncology toward pediatric cancer patients has moved forward more slowly than with adults...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643134/ https://www.ncbi.nlm.nih.gov/pubmed/38023209 http://dx.doi.org/10.3389/fonc.2023.1279953 |
_version_ | 1785134288136568832 |
---|---|
author | Marshall, Mark Ivanovich, Jennifer Schmitt, Morgan Helvie, Amy Langsford, Lisa Casterline, Jennifer Ferguson, Michael |
author_facet | Marshall, Mark Ivanovich, Jennifer Schmitt, Morgan Helvie, Amy Langsford, Lisa Casterline, Jennifer Ferguson, Michael |
author_sort | Marshall, Mark |
collection | PubMed |
description | Precision oncology is defined as the selection of an effective treatment for a cancer patient based upon genomic profiling of the patient’s tumor to identify targetable alterations. The application of precision oncology toward pediatric cancer patients has moved forward more slowly than with adults but is gaining momentum. Clinical and pharmaceutical advances developed over the past decade for adult cancer indications have begun to move into pediatric oncology, expanding treatment options for young high-risk and refractory patients. As a result, the FDA has approved 23 targeted drugs for pediatric cancer indications, moving targeted drugs into the standard of care. Our precision oncology program is in a medium sized children’s hospital, lacking internal sequencing capabilities and bioinformatics. We have developed methods, medical and business partnerships to provide state-of-the-art tumor characterization and targeted treatment options for our patients. We present here a streamlined and practical protocol designed to enable any oncologist to implement precision oncology options for their patients. |
format | Online Article Text |
id | pubmed-10643134 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106431342023-01-01 Pediatric precision oncology: “better three hours too soon than a minute too late” Marshall, Mark Ivanovich, Jennifer Schmitt, Morgan Helvie, Amy Langsford, Lisa Casterline, Jennifer Ferguson, Michael Front Oncol Oncology Precision oncology is defined as the selection of an effective treatment for a cancer patient based upon genomic profiling of the patient’s tumor to identify targetable alterations. The application of precision oncology toward pediatric cancer patients has moved forward more slowly than with adults but is gaining momentum. Clinical and pharmaceutical advances developed over the past decade for adult cancer indications have begun to move into pediatric oncology, expanding treatment options for young high-risk and refractory patients. As a result, the FDA has approved 23 targeted drugs for pediatric cancer indications, moving targeted drugs into the standard of care. Our precision oncology program is in a medium sized children’s hospital, lacking internal sequencing capabilities and bioinformatics. We have developed methods, medical and business partnerships to provide state-of-the-art tumor characterization and targeted treatment options for our patients. We present here a streamlined and practical protocol designed to enable any oncologist to implement precision oncology options for their patients. Frontiers Media S.A. 2023-10-30 /pmc/articles/PMC10643134/ /pubmed/38023209 http://dx.doi.org/10.3389/fonc.2023.1279953 Text en Copyright © 2023 Marshall, Ivanovich, Schmitt, Helvie, Langsford, Casterline and Ferguson https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Marshall, Mark Ivanovich, Jennifer Schmitt, Morgan Helvie, Amy Langsford, Lisa Casterline, Jennifer Ferguson, Michael Pediatric precision oncology: “better three hours too soon than a minute too late” |
title | Pediatric precision oncology: “better three hours too soon than a minute too late” |
title_full | Pediatric precision oncology: “better three hours too soon than a minute too late” |
title_fullStr | Pediatric precision oncology: “better three hours too soon than a minute too late” |
title_full_unstemmed | Pediatric precision oncology: “better three hours too soon than a minute too late” |
title_short | Pediatric precision oncology: “better three hours too soon than a minute too late” |
title_sort | pediatric precision oncology: “better three hours too soon than a minute too late” |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643134/ https://www.ncbi.nlm.nih.gov/pubmed/38023209 http://dx.doi.org/10.3389/fonc.2023.1279953 |
work_keys_str_mv | AT marshallmark pediatricprecisiononcologybetterthreehourstoosoonthanaminutetoolate AT ivanovichjennifer pediatricprecisiononcologybetterthreehourstoosoonthanaminutetoolate AT schmittmorgan pediatricprecisiononcologybetterthreehourstoosoonthanaminutetoolate AT helvieamy pediatricprecisiononcologybetterthreehourstoosoonthanaminutetoolate AT langsfordlisa pediatricprecisiononcologybetterthreehourstoosoonthanaminutetoolate AT casterlinejennifer pediatricprecisiononcologybetterthreehourstoosoonthanaminutetoolate AT fergusonmichael pediatricprecisiononcologybetterthreehourstoosoonthanaminutetoolate |